Altay Therapeutics
PrivateLast Round
Series A
Oct 2, 2026
Est. Valuation
$2.14M
Total Funding Raised
$3.73M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Altay Therapeutics is a biotechnology company that develops novel small-molecule inhibitors of transcription factors to treat neuromuscular disorders, cancer, and chronic inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Altay Therapeutics Comparables
Compare Altay Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Talus Bio | 83% | |
| Tvardi | 79% | |
| HotSpot Therapeutics | 79% |
Altay Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 2, 2026 | ||||
| Grant | Sep 15, 2023 | ||||
| Grant | Sep 1, 2023 | ||||
| Grant | Jul 11, 2023 | ||||
| Seed | Sep 21, 2022 | ||||
Accelerator | Mar 16, 2020 |
Key People
Founding team and executive leadership
Altay Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| A. M. Pappas & Associates | Series A |
| RM Global Partners | Series A |
| NIH RADx | Grant |
| Fountain Healthcare Partners | Series A |
| HealthCap | Series A |
| Solve FSHD | Grant, Seed |
| Y Combinator | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 2, 2026
$16M round raised
- Sep 11, 2026
Monthly visitors grew 67% MoM, reaching 2.3K.
Recent news
Latest coverage and updates
- receives_financingOct 14, 2026
On Oct 14th '26, Altay Therapeutics, Inc. closes a $37M Series A financing co-led by Sound Bioventures and HealthCap, with participation from Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital and Global BioAccess Fund, to advance DX5057 through clinical development and support its drug-discovery platform in California.
Altay Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Altay Therapeutics's valuation, stock price, and market status.
Is Altay Therapeutics a public or private company?
Altay Therapeutics is a private company.
What is the current stock price of Altay Therapeutics?
Altay Therapeutics is a private company, so its shares have no public market price. Caplight tracks Altay Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Altay Therapeutics worth (valuation)?
Altay Therapeutics's valuation is estimated at $2.1M based on funding round data.
Can I buy Altay Therapeutics stock?
Altay Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Altay Therapeutics's last funding round?
Altay Therapeutics's most recent funding round was Series A on October 2, 2026.
Who are the main investors in Altay Therapeutics?
Key investors in Altay Therapeutics include HealthCap, Solve FSHD, Sound Bioventures.
Will Altay Therapeutics IPO soon?
No public IPO plans have been announced for Altay Therapeutics.
How can I track Altay Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Altay Therapeutics's shares on secondary markets.